Mass cytometry has emerged as a new state-of-the-art technology that enables in-depth characterization of cellular populations and functions at a single cell resolution. We describe the application of this technology to deeply phenotype the blood and bone marrow components of multiple myeloma patients in a clinical setting. This technology allows for simultaneous quantification of more than 40 markers, overcoming the challenges of traditional fluorescence-based flow cytometry.
Keywords: Barcoding; Bone marrow; CyTOF; Immunophenotyping; Mass cytometry; Multiple myeloma; Peripheral blood; Single cell; Smart tube.